These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 16645899)

  • 41. ME-3407, a new antiulcer agent, inhibits acid secretion by interfering with redistribution of H(+)-K(+)-ATPase.
    Urushidani T; Muto Y; Nagao T; Yao X; Forte JG
    Am J Physiol; 1997 May; 272(5 Pt 1):G1122-34. PubMed ID: 9176222
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Comparative study of proton pump inhibitors].
    Herszényi L; Tulassay Z
    Orv Hetil; 2001 Sep; 142(36):1953-61. PubMed ID: 11680100
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The efficacy of proton-pump inhibitors in the treatment of acid-dependent diseases].
    Tkach SM
    Lik Sprava; 1997; (3):30-5. PubMed ID: 9377349
    [No Abstract]   [Full Text] [Related]  

  • 44. Peptic ulcer: a problem almost solved.
    Baron JH
    J R Coll Physicians Lond; 1997; 31(5):512-20. PubMed ID: 9429188
    [No Abstract]   [Full Text] [Related]  

  • 45. Pharmacological evaluation of newly synthesized organotin IV complex for antiulcer potential.
    Azmatullah S; Khan AU; Qazi NG; Nadeem H; Irshad N
    BMC Pharmacol Toxicol; 2022 Jul; 23(1):58. PubMed ID: 35906691
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Control of gastric acid secretion in health and disease.
    Schubert ML; Peura DA
    Gastroenterology; 2008 Jun; 134(7):1842-60. PubMed ID: 18474247
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The pharmacology of the gastric acid pump: the H+,K+ ATPase.
    Sachs G; Shin JM; Briving C; Wallmark B; Hersey S
    Annu Rev Pharmacol Toxicol; 1995; 35():277-305. PubMed ID: 7598495
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Proton pump inhibitors].
    Schubert-Zsilavecz M; Stark H
    Pharm Unserer Zeit; 2005; 34(3):194-9. PubMed ID: 15940951
    [No Abstract]   [Full Text] [Related]  

  • 49. Pharmacologic properties of proton pump inhibitors.
    Welage LS
    Pharmacotherapy; 2003 Oct; 23(10 Pt 2):74S-80S. PubMed ID: 14587961
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gastric acid secretion: activation and inhibition.
    Sachs G; Prinz C; Loo D; Bamberg K; Besancon M; Shin JM
    Yale J Biol Med; 1994; 67(3-4):81-95. PubMed ID: 7502535
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The mode of action of colloidal bismuth subcitrate.
    Lee SP
    Scand J Gastroenterol Suppl; 1991; 185():1-6. PubMed ID: 1957120
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    de Korwin JD; Ducrotté P; Vallot T
    Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of short-term treatment with regular or high doses of omeprazole on the detection of Helicobacter pylori in bleeding peptic ulcer patients.
    Udd M; Miettinen P; Palmu A; Julkunen R
    Scand J Gastroenterol; 2003 Jun; 38(6):588-93. PubMed ID: 12825865
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quadruple treatments for Helicobacter pylori.
    Mascitelli L; Pezzetta F
    Lancet; 2003 Jan; 361(9351):86. PubMed ID: 12517510
    [No Abstract]   [Full Text] [Related]  

  • 55. Management of Helicobacter pylori infection.
    Costa F; D'Elios MM
    Expert Rev Anti Infect Ther; 2010 Aug; 8(8):887-92. PubMed ID: 20695744
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies.
    Bardhan KD; Cherian P; Bishop AE; Polak JM; Romanska H; Perry MJ; Rowland A; Thompson M; Morris P; Schneider A; Fischer R; Ng W; Lühmann R; McCaldin B
    Am J Gastroenterol; 2001 Jun; 96(6):1767-76. PubMed ID: 11419827
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Substituted methoxybenzyl-sulfonyl-1H-benzo[d]imidazoles evaluated as effective H
    Rajesh R; Manikandan A; Sivakumar A; Ramasubbu C; Nagaraju N
    Eur J Med Chem; 2017 Oct; 139():454-460. PubMed ID: 28818769
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clarithromycin-based triple therapy for Helicobacter pylori treatment in peptic ulcer patients.
    Felga G; Silva FM; Barbuti RC; Navarro-Rodriguez T; Zaterka S; Eisig JN
    J Infect Dev Ctries; 2010 Nov; 4(11):712-6. PubMed ID: 21252448
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications--future research needs.
    Graham DY
    Am J Med; 2001 Jan; 110(1A):58S-61S. PubMed ID: 11166000
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Proton pump inhibitors in developmental period medicine].
    Czerwionka-Szaflarska M; Brazowski J
    Pol Merkur Lekarski; 2007 Feb; 22(128):154-8. PubMed ID: 17598663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.